Insights

Top broker tips Mesoblast (ASX:MSB) share price to double in value

This biotech company’s shares have been tipped to shoot higher…
The post Top broker tips Mesoblast (ASX:MSB) share price to double in value appeared first on The Motley Fool Australia. –

The Mesoblast limited (ASX: MSB) share price is having another year to forget in 2021.

Since the turn of the year, the biotechnology company’s shares have fallen 27% to $1.69.

Is the Mesoblast share price good value now?

The good news for investors and the company’s long-suffering shareholders is that one leading broker believes the Mesoblast share price could be very good value.

According to a note out of Bell Potter, its analysts have retained their speculative buy rating but trimmed their price target slightly to $3.45.

Based on the current Mesoblast share price, this price target implies potential upside of greater than 100% over the next 12 months.

Why is the broker bullish?

Bell Potter remains positive on Mesoblast due to the belief that its remestemcel-L product is approaching a key inflection point in the fourth quarter of calendar year 2021.

It notes that the company was hit with an unexpected request for more information from the US Food and Drug Agency (FDA) last year for remestemcel-L’s use in paediatric GvHD. While this has delayed the time to first revenues from the product, Bell Potter is encouraged with recent developments.

The broker explained: “Based on recent discussions with FDA’s CBER, there is no further talk about a confirmatory adult trial, which is a key positive and reflects that the efficacy of this life saving therapy is undeniable. The OTAT meeting to be held in 4QCY21 to discuss critical aspects of the manufacturing and quality control process including potency assays is now the gating event to a potential BLA resubmission with a 6 month review clock.”

What else?

Bell Potter notes that those potency assays are also key for label expansion into treating COVID-19 ARDS.

Pleasingly, the broker highlights that “initial FDA feedback is that the assays currently in development appear to be reasonable based on in vitro data.”

Furthermore, with the next trial likely to be focused on patients <65 years of age, where there was strong survival benefit observed, Bell Potter believes this increases the chances of a positive outcome.

Another reason the broker is bullish on the Mesoblast share price is that, based on the above, it believes the company’s game-changing deal with Novartis will go ahead.

It commented: “We continue to believe there is strong likelihood of closure in 2HCY21 (however timing could be pushed from 3QCY21 to 4QCY21 in our view) based on the survival benefit observed in the recent trial. As a reminder closing of this deal will provide US$50m to MSB (US$25m in cash and balance in equity) and will be a key catalyst for the stock.”

The post Top broker tips Mesoblast (ASX:MSB) share price to double in value appeared first on The Motley Fool Australia.

Should you invest $1,000 in Mesoblast right now?

Before you consider Mesoblast, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Mesoblast wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

ASX 200 Weekly Wrap: ASX puts earnings season to bed with another rise

These were the worst performing ASX 200 shares last week

ASX 200 midday update: TechnologyOne hits record high, lithium miners rise

Mesoblast (ASX:MSB) shares rise as CEO reassures market on new FDA questions
ASX 200 rises, Harvey Norman falls, Mesoblast sinks

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!